prison

The risk matrix: Drug-related deaths in prisons in England and Wales, 2015–2020

Duke, K., Gleeson, H., MacGregor, S., & Thom, B. (2023). The risk matrix: Drug-related deaths in prisons in England and Wales, 2015–2020. Journal of Community Psychology, 1– 22. https://doi.org/10.1002/jcop.22989
Publication Date

This article explores the factors contributing to drug-related deaths in English and Welsh prisons between 2015 and 2020. Based on content analysis of all Prison and Probation Ombudsman ‘other non-natural’ fatal incident investigation reports, descriptive statistics were generated. Qualitative analysis explored the circumstances surrounding deaths and key risk factors. Most deaths were of men, whose mean age was 39 years.

Treatment of Drug Use Disorders and Associated Mental Health Disorders in Prison Settings and Forensic Hospitals

Published by
UNODC
Publication Date

This discussion paper was prepared by UNODC following various requests from the Member States for technical assistance on the treatment of drug use disorders and associated mental health disorders in prison settings.

Training of Trainer (TOT) on Drug Treatment and Management for prison officers

As part of Dhaka Ahsania Mission (DAM) capacity building initiatives with prison staff for the better management of drug dependent prisoners, a four-day long Training of Trainers (ToT) on Drug Treatment and Management Training for prison staff was held on 25 July 2022. The training was organized by the Bangladesh Prisons Department and DAM with the technical assistance of the German development aid agency GIZ and funded by the British Government under the JPRPHRPC project

Third European Conference on Healthcare in Prison

Lisbon, Portugal,

Date: 21-22 November
Location: LxAddictions conference site

Health Without Barriers — the European Federation for Prison Health — is organising its Third European Conference on Healthcare in Prison in Lisbon in the margins of Lisbon Addictions 2022.

The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis

The prevalence of comorbid serious mental illnesses and substance use disorders in prison populations: a systematic review and meta-analysis Baranyi, Gergő et al. The Lancet Public Health, Volume 7, Issue 6, e557 - e568
Publication Date

Background

Comorbid mental illnesses and substance use disorders are associated with adverse criminal, social, and health outcomes. Yet, their burden is not reliably known among prison populations. We therefore aimed to estimate the prevalence of comorbid serious mental illnesses and substance use disorders (dual disorders) among people in prison worldwide.

Structural violence and the need for compassionate use of methadone in Mexico

Romero-Mendoza, M., Peláez-Ballestas, I., Almanza-Avendaño, A.M. et al. Structural violence and the need for compassionate use of methadone in Mexico. BMC Public Health 22, 606 (2022). https://doi.org/10.1186/s12889-022-12955-x
Publication Date

Abstract

Background

Epidemiological data from Mexico have documented an increase in heroin use in the last decade. However, there is no comprehensive care strategy for heroin users, especially those who have been accused of a crime.

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021

Thakrar AP, Alexander GC, Saloner B. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. JAMA Netw Open. 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807

Source:

Thakrar AP, Alexander GC, Saloner B. Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021. JAMA Netw Open. 2021;4(12):e2138807. doi:10.1001/jamanetworkopen.2021.38807

 

Review of Alternatives to Incarceration Efforts Worldwide

Diplomacy Lab Project 2010304, U.S. Department of State, Secretary’s Office of Global Partnerships and Bureau of International Narcotics and Law Enforcement Affairs and John Jay College of Criminal Justice
Publication Date

Substance use disorders are reoccurring chronic, often relapsing disease that affect the brain and should be treated within the public health arena similar to other diseases such as diabetes and heart disease. This understanding, however, does not easily find its way into public or social policy.